Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Acasti Pharma (ACST)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 82,816
  • Shares Outstanding, K 78,128
  • Annual Sales, $ 0 K
  • Annual Income, $ -16,780 K
  • 60-Month Beta 1.23
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.61

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.08
  • Number of Estimates 2
  • High Estimate -0.05
  • Low Estimate -0.11
  • Prior Year -0.96
  • Growth Rate Est. (year over year) +91.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.91 +17.57%
on 02/22/19
1.12 -4.47%
on 03/04/19
+0.15 (+16.29%)
since 02/19/19
3-Month
0.66 +62.11%
on 12/27/18
1.15 -6.97%
on 01/15/19
+0.37 (+52.84%)
since 12/19/18
52-Week
0.43 +148.81%
on 08/16/18
1.80 -40.56%
on 10/01/18
+0.06 (+5.93%)
since 03/19/18

Most Recent Stories

More News
Acasti Pharma to Present at the Oppenheimer 29th Annual Healthcare Conference on March 19th

Acasti Pharma Inc. ("Acasti or the "Company") (NASDAQ: ACST - TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre(R)...

ACST.VN : 1.410 (unch)
ACST : 1.07 (+0.94%)
Acasti Pharma Recognized in TSX Venture Exchange's 2019 Venture 50

Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST - TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate...

ACST.VN : 1.410 (unch)
ACST : 1.07 (+0.94%)
Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019

Planned Enrollment targets achieved in both TRILOGY studies with over 74% of patients randomized at more than 150 clinical sites

ACST.VN : 1.410 (unch)
ACST : 1.07 (+0.94%)
Acasti Pharma Schedules Third Quarter Fiscal 2019 Conference Call

Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST - TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate...

ACST.VN : 1.410 (unch)
ACST : 1.07 (+0.94%)
4 Healthcare Stocks Looking To Set January Highs

CORAL GABLES, FL/ ACCESSWIRE / January 9, 2019 / The is predicated on the notion that as diseases become more advanced and difficult to treat, companies responsible for creating treatment options will...

ATOS : 4.46 (+1.36%)
ACST : 1.07 (+0.94%)
VSTM : 3.42 (+1.18%)
Acasti Pharma Awarded Broad Composition-of-Matter and Method of Use Patents by the European Patent Office

Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST - TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate...

ACST.VN : 1.410 (unch)
ACST : 1.07 (+0.94%)
Acasti Pharma Announces TRILOGY Phase 3 Trials of CaPre(R) in Patients with Severe Hypertriglyceridemia Has Now Exceeded 65% Randomization, and More Than 100 Patients (>20%) Have Completed Their 6 Month Treatment Plan

Acasti Pharma Inc. ("Acasti or the "Company") (NASDAQ: ACST - TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre(R)...

ACST.VN : 1.410 (unch)
ACST : 1.07 (+0.94%)
Generic Industry on Path to Recovery: 3 Hot Picks for 2019

The stability in the industry sets the stage for players to get back on growth track. Here we discuss three stocks picks from the industry.

MYL : 28.52 (+1.21%)
RDY : 39.77 (+1.77%)
TEVA : 16.69 (+0.30%)
BHC : 25.46 (+3.75%)
ACST : 1.07 (+0.94%)
Acasti Pharma Achieves Planned Enrollment Targets for TRILOGY Phase 3 Trials of CaPre(R) in Patients with Severe Hypertriglyceridemia

Acasti Pharma Inc. ("Acasti or the "Company") (NASDAQ: ACST - TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre(R)...

ACST.VN : 1.410 (unch)
ACST : 1.07 (+0.94%)
Acasti Pharma to Present at the 11th Annual LD Micro Main Event

Laval, Quebec / ACCESSWIRE / November 27, 2018 / Acasti Pharma Inc. (NASDAQ: ACST) (TSX-V: ACST) (the "Company" or "Acasti Pharma"), a biopharmaceutical innovator focused on the research, development and...

ACST.VN : 1.410 (unch)
ACST : 1.07 (+0.94%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade ACST with:

Business Summary

Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R)...

See More

Key Turning Points

2nd Resistance Point 1.10
1st Resistance Point 1.08
Last Price 1.07
1st Support Level 1.04
2nd Support Level 1.02

See More

52-Week High 1.80
Fibonacci 61.8% 1.28
Fibonacci 50% 1.12
Last Price 1.07
Fibonacci 38.2% 0.95
52-Week Low 0.43

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar